Aiwu Ruth He MD

Oncology•New York, NY

Associate Professor, Medicine, Georgetown University School of Medicine

Request appointment

161 Fort Washington AvenueNew York, NY 10032
Book by Phone+1(240) 981-5257

Overview of Dr. He

I am a board certified medical oncologist focus on GI cancer.

Education & Training

MedStart Georgetown University HospitalFellowship, Medical Oncology, 2004 - 2006
Hunan Medical UniversityClass of 1991

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 2025 - 2027
CT State Medical License 2025 - 2026
DC State Medical License 2004 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer
UNKNOWN
PHASE1
Sunitinib and Capecitabine for First Line Colon Cancer
TERMINATED
PHASE2
ABT-888 and Temozolomide for Liver Cancer
TERMINATED
PHASE2

Publications & Presentations

PubMed

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.
Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka
JAMA Oncology. 2026-07-09
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: Primary results from the phase IIIb TOURMALINE study.
Do-Youn Oh, Masafumi Ikeda, Teresa Macarulla, Aiwu Ruth He, Joon Oh Park
Journal of Hepatology. 2026-07-06
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).
Thomas Yau, Peter R Galle, Thomas Decaens, Bruno Sangro, Shukui Qin
Future Oncology. 2026-04-01

Press Mentions

Opdivo + Yervoy Approved as First-Line Tx for Hepatocellular CarcinomaMay 19th, 2025
Bristol Myers Scores FDA Approval for Opdivo-Yervoy Combination as First-Line HCC TherapyApril 14th, 2025
SPTBN1 Inhibits Inflammatory Responses and Hepatocarcinogenesis via the Stabilization of SOCS1 and Downregulation of p65 in Hepatocellular CarcinomaFebruary 20th, 2021

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem KeyCare PPO
BCBS Blue Card PPO
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Multiplan PHCS PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment